The three direct-acting antiviral combination of ombitasvir, paritaprevir, ritonavir, and dasabuvir (3D regimen) is a combination therapy that was recently approved for the treatment of genotype-1 chronic hepatitis C virus infection. |
Potential drug–drug interactions with the 3D regimen were identified by applying pharmacokinetic study data to known routes of metabolism and disposition of more than 200 prescription and over-the-counter drugs. |
The majority of concomitant medications assessed are compatible with 3D therapy. Where interaction is possible, guidance on dose adjustment and/or clinical monitoring are provided. |
1 Introduction
2 Metabolic Characteristics of 3D Regimen Components
Transporter | Substrate | Inhibitor |
---|---|---|
Ombitasvir | P-gp | |
Paritaprevir | P-gp, BCRP, OATP1B1/B3 | P-gp, BCRP, OATP1B1/B3 |
Dasabuvir | P-gp, BCRP | P-gp, BCRP |
Ritonavir | P-gp | P-gp, BCRP |
2.1 DDI Studies with the 3D Regimen
3 DDI Potential of Concomitantly Administered Medications by Therapeutic Class
Class (use in pivotal trials)a
| No expected DDI | Require possible dose adjustment | Contra-indicated |
---|---|---|---|
Analgesics/anti-inflammatory agents (30 and 11 % of patients received non-opioid and opioid analgesics, respectively) | Acetaminophenb
Aspirin Buprenorphineb
Celecoxib Codeine Diclofenac Etodolac Fenoprofen Flurbiprofen Ibuprofen Indomethacin Ketoprofen Ketorolac Methadoneb
Morphine Naloxoneb
Naproxen Piroxicam Sulindac Suprofen | Fentanyl (↓) Hydrocodoneb (↓) Hydromorphone (↓) Meloxicam (↓) Meperidine (pethidine) (↓) Oxycodone (↓) Tramadol (↓) | None |
Diuretics (26 % of patients)c
| Amiloride Chlorthalidone Hydrochloro-thiazide Torsemide Triamterene | Furosemide (↓ ≤50 %)b,d
Xipamide (↓)c
| None |
Antihypertensive agents (26 % of patients)c
| Atenolol Azilsartan Betaxolol Bisoprolol Captopril Carteolol Fosinopril Lisinopril Metoprolol Nadolol Nebivolol Perindopril Propranolol Quinopril Ramipril Sotalol Spironolactone Timolol Zofenopril | Amlodipine (↓50 %)b
Candesartan (↓) Enalapril (↓) Eprosartan (↓) Irbesartan (↓) Losartan (↓) Olmesartan (↓) Telmisartan (↓) Valsartan (↓) Start lowest dose: Diltiazem Nicardipine Nifedipine Nitrendipine Verapamil Avoid use: Nisoldipine Felodipine | None |
Antidiabetic agents (5 % of patients) | Acarbose Glimepiride Glipizide Metforminb
Pioglitazone Rosiglitazone Sitagliptine
Tolbutamide Vildagliptin | Repaglinide (↓) Glibenclamide (glyburide) (↓) Saxagliptin (limit dose to 2.5 mg once daily) | None |
α1-Adrenergic blockers (26 % of patients)c
| None | Use with caution: Doxazosin (↓) Avoid use: Tamsulosin | Alfuzosin |
Hypnotic/sedative agentsd (2 % of patients) | Oxazepam Temazepam Zolpidemb
| Alprazolam (↓)b
Clonazepam (↓) Diazepamb (↑)d
Estazolam (↓) Eszopiclone (↓) Flunitrazepam (↓) Lorazepam (↓) Midazolam (parenteral)d
Prazepam (↓) Quazepam (↓) Zaleplon (↓) Zopiclone (↓) | Midazolam (oral) Triazolam |
Antibiotics and antifungals (anti-infectives) (7 % of patients) | Amoxicillin Azithromycin Cephalexin Ciprofloxacin Clarithromycine
Sulfamethoxazole/trimethoprimb
Caspofungin Micafungin Anidulafungin | Ketoconazole (limit dose to 200 mg)b
Itraconazole (limit dose to 200 mg) Use with caution: Posaconazole (↓) Voriconazolef
| Fusidic acid Rifampin (rifampicin) |
Phosphodiesterase type 5 inhibitors (<1 % of patients) | None | Sildenafil (↓ for erectile dysfunction)d,g
Tadalafil (↓)d,h
Vardenafil (↓)d,i
Avoid use: Avanafil | Sildenafil (for PAH) |
Antidepressants (22 % of patients) | Bupropiond
Citalopram Duloxetineb
Escitalopramb
Fluoxetine Milnacipran Paroxetine | Fluvoxamined
Mirtazapine (↓) Reboxetine (↓) Sertraline (↓) Trazodone (↓) Venlafaxine (↓) | St. John’s Wort |
Antacids/proton pump inhibitors (16 % of patients) | Almagate Aluminum hydroxide Calcium carbonate Cimetidine Famotidine Magaldrate Magnesium hydroxide Ranitidine | Dexlansoprazole (↑)d
Esomeprazole (↑)d
Lansoprazole (↑)d
Omeprazole (↑)b,d
Pantoprazole (↑)d
Rabeprazole (↑)d
| None |
Antiplatelet agents/anticoagulants (26 % of patients)c
| Acenocoumarold
Aspirin Enoxaparin Fluindione Fondaparinux Phenprocoumand
Prasugreld
Warfarina,b
| Apixaban (restrict dose to 2.5 mg twice daily) Dabigatran (↓)d
Avoid use: Clopidogrel Rivaroxaban | None |
Antiarrhythmic agents (26 % of patients)c
| Digoxinb,d
Flecainided
Mexiletined
| Use with caution: Amiodarone (↓)d
Disopyramide (↓)d
Dronedarone (↓)d
Propafenone (↓)d
Quinidine (↓)d
| None |
Lipid-modifying agents (2 % of patients) | Choline fenofibrated
Colesevelemj
Colestipolj
Fenofibrated
Mipomersen Niacin Omega-3 fatty acids | Pravastatin (↓50 %)b
Rosuvastatin (limit maximum daily dose to 5–10 mg)b
Start lowest dose: Cerivastatin Ezetimibe Fluvastatin Pitavastatin Avoid use: Atorvastatin | Gemfibrozilb
Lovastatin Simvastatin |
β-Adrenergic agonists (14 % of patients received β-adrenergic agonists/anti-allergics/respiratory agents) | Albuterol (salbutamol) | Use with caution: Formoterol (↓)d
Not recommended: Salmeterol | None |
Antiepileptic agents (3 % of patients) | Felbamate Gabapentin Levetiracetam Sodium valproated
Topiramate Vigabatrin | Lamotrigine (↑)d
Use with caution: Tiagabine (↓) Zonisamide (↓) | Carbama-zepine Phenytoin Phenobarbital |
Steroidsc (8 % of patients) | Beclomethasone Ciclesonide | Use with caution: Budesonide (↓)f
Dexamethasone (↓) Fluticasone (↓)f
Methyl-prednisolone (↓) Mometasone (↓) Prednisone (↓) Triamcinolone (↓) | None |
Contraceptives (<1 % of patients received hormonal contraceptives) | Progestin-only OCPsb
Non-hormonal contraceptives | None | Ethinyl estradiol-containing OCPsb
|
Thyroid replacement therapy (7 % of patients) | None | Levothyroxined
| None |